N
NATERA INC
NASDAQ: NTRA (Natera, Inc.)
Last update: 15 hours ago310.67
-53.09 (-14.59%)
| Previous Close | 363.76 |
| Volume | 5,777,243 |
| Price / Earnings (Forward) | 5.05 |
| Price / Sales | 20.24 |
| Price / Book | 30.83 |
| 52 Weeks Range |
| Profit Margin | -10.36% |
| Operating Margin (TTM) | -15.78% |
| Diluted EPS (TTM) | -1.47 |
| Quarterly Revenue Growth (YOY) | 36.50% |
| Total Debt/Equity (MRQ) | 15.78% |
| Current Ratio (MRQ) | 3.87 |
| Operating Cash Flow (TTM) | 153.12 M |
| Levered Free Cash Flow (TTM) | 120.93 M |
| Return on Assets (TTM) | -8.87% |
| Return on Equity (TTM) | -18.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Natera, Inc. | Mixed | Bullish |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 2.0 |
| Timing 35% | -1.3 |
| AI Technical info | NA |
| Technical Oscillators info | -0.5 |
| Technical Moving Averages info | -2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | 0.0 |
| Environment | ×1.05 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | +36.7% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | 0.2 |
| Final Score | -0.48 |
Select this tab to load the latest available analysis.
|
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 3.24% |
| % Held by Institutions | 96.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Castle Hook Partners Lp | 30 Jun 2026 | 2,596,276 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BROPHY MICHAEL BURKES | - | 413.92 | -5,858 | -2,424,733 |
| CHAPMAN STEVEN LEONARD | - | 402.96 | -9,495 | -3,826,132 |
| FESKO JOHN | - | 412.12 | -1,981 | -816,413 |
| MOSHKEVICH SOLOMON | - | 394.14 | -5,591 | -2,203,632 |
| RABINOWITZ DANIEL | - | 411.86 | -2,193 | -903,215 |
| RABINOWITZ MATTHEW | - | 401.14 | -2,466 | -989,221 |
| SHEENA JONATHAN | - | 409.07 | -590 | -241,354 |
| Aggregate Net Quantity | -28,174 | |||
| Aggregate Net Value ($) | -11,404,701 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 404.80 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BROPHY MICHAEL BURKES | Officer | 03 Nov 2026 | Automatic sell (-) | 470 | 388.63 | 182,656 |
| FESKO JOHN | Officer | 02 Nov 2026 | Automatic sell (-) | 302 | 378.92 | 114,434 |
| BROPHY MICHAEL BURKES | Officer | 02 Nov 2026 | Automatic sell (-) | 325 | 378.92 | 123,149 |
| RABINOWITZ DANIEL | Officer | 02 Nov 2026 | Automatic sell (-) | 341 | 378.92 | 129,212 |
| MOSHKEVICH SOLOMON | Officer | 02 Nov 2026 | Automatic sell (-) | 3,419 | 378.92 | 1,295,527 |
| CHAPMAN STEVEN LEONARD | Officer | 02 Nov 2026 | Automatic sell (-) | 3,801 | 378.92 | 1,440,275 |
| SHEENA JONATHAN | Director | 02 Nov 2026 | Automatic sell (-) | 112 | 378.92 | 42,439 |
| RABINOWITZ MATTHEW | Officer | 02 Nov 2026 | Automatic sell (-) | 748 | 378.92 | 283,432 |
| BROPHY MICHAEL BURKES | Officer | 30 Oct 2026 | Automatic sell (-) | 1,906 | 414.30 | 789,656 |
| CHAPMAN STEVEN LEONARD | Officer | 28 Oct 2026 | Automatic sell (-) | 3,430 | 424.42 | 1,455,761 |
| BROPHY MICHAEL BURKES | Officer | 28 Oct 2026 | Automatic sell (-) | 1,198 | 424.42 | 508,455 |
| RABINOWITZ DANIEL | Officer | 28 Oct 2026 | Automatic sell (-) | 968 | 424.42 | 410,839 |
| MOSHKEVICH SOLOMON | Officer | 28 Oct 2026 | Automatic sell (-) | 1,162 | 424.42 | 493,176 |
| FESKO JOHN | Officer | 28 Oct 2026 | Automatic sell (-) | 898 | 424.42 | 381,129 |
| SHEENA JONATHAN | Director | 28 Oct 2026 | Automatic sell (-) | 187 | 424.42 | 79,367 |
| BROPHY MICHAEL BURKES | Officer | 28 Oct 2026 | Automatic sell (-) | 1,178 | 424.42 | 499,967 |
| CHAPMAN STEVEN LEONARD | Officer | 27 Oct 2026 | Automatic sell (-) | 2,264 | 410.82 | 930,096 |
| BROPHY MICHAEL BURKES | Officer | 27 Oct 2026 | Automatic sell (-) | 781 | 410.82 | 320,850 |
| RABINOWITZ DANIEL | Officer | 27 Oct 2026 | Automatic sell (-) | 884 | 410.82 | 363,165 |
| RABINOWITZ MATTHEW | Officer | 27 Oct 2026 | Automatic sell (-) | 1,718 | 410.82 | 705,789 |
| MOSHKEVICH SOLOMON | Officer | 27 Oct 2026 | Automatic sell (-) | 1,010 | 410.82 | 414,928 |
| FESKO JOHN | Officer | 27 Oct 2026 | Automatic sell (-) | 781 | 410.82 | 320,850 |
| SHEENA JONATHAN | Director | 27 Oct 2026 | Automatic sell (-) | 291 | 410.82 | 119,549 |
| Show more | ||||||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |